Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats

Drug Metabolism and Disposition

Volumn 36, Issue 11, 2008, Pages 2277-2286

  Zordoky, Beshay N M ^a   Aboutabl, Mona E ^a   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

11,12 EPOXY 8,11,14 EICOSATRIENOIC ACID; 14,15 EPOXY 8,11,14 EICOSATRIENOIC ACID; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; 8,9 EPOXY 8,11,14 ICOSATRIENOIC ACID; ARACHIDONIC ACID DERIVATIVE; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 2C11; CYTOCHROME P450 2E1; CYTOCHROME P450 4A; CYTOCHROME P450 4A3; EPOXIDE HYDROLASE; ISOPRENALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; ENZYME INDUCTION; GENE EXPRESSION REGULATION; HEART HYPERTROPHY; HEART WEIGHT; KIDNEY; LIVER; LUNG; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ARACHIDONIC ACID; CARDIOMEGALY; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; ISOPROTERENOL; MALE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 54349101231     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023077     Document Type: Article

References (38)

1. Baldwin SJ, Bramhall JL, Ashby CA, Yue L, Murdock PR, Hood SR, Ayrton AD, and Clarke SE (2006) Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). Drug Metab Dispos 34:1063-1069.
2. Barakat MM, El-Kadi AO, and du Souich P (2001) L-NAME prevents in vivo the inactivation but not the down-regulation of hepatic cytochrome P450 caused by an acute inflammatory reaction. Life Sci 69:1559-1571.
3. Bleicher KB, Pippert TR, Glaab WE, Skopek TR, Sina JF, and Umbenhauer DR (2001) Use of real-time gene-specific polymerase chain reaction to measure RNA expression of three family members of rat cytochrome P450 4A. J Biochem Mol Toxicol 15:133-142.
4. Braunwald E and Bristow MR (2000) Congestive heart failure: fifty years of progress. Circulation 102:IV14-IV23.
5. Campbell WB (2000) New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol Sci 21:125-127.
6. Carreño JE, Apablaza F, Ocaranza MP, and Jalil JE (2006) Cardiac hypertrophy: molecular and cellular events. Rev Esp Cardiol 59:473-486.
7. Chábová VC, Kramer HJ, Vanecková I, Vernerová Z, Eis V, Tesar V, Skaroupková P, Thumová M, Schejbalová S, Husková Z, et al. (2007) Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol 47:145-159.
8. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, and Schenkman JB (2004) Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 32:840-847.
9. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, Steenbergen C, Zeldin DC, and Goldstein JA (2007) Detection of human CYP2C8, CYP2C9 and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35:682-688.
10. Elbekai RH and El-Kadi AO (2006) Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112:564-587.
11. Hirasawa F, Kawagoe M, Arany S, Koizumi Y, Ueno Y, and Sugiyama T (2005) Styrene monomer primarily induces CYP2B1 mRNA in rat liver. Xenobiotica 35:1089-1099.
12. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, Yamaguchi O, Mano T, Matsumura Y, Ueno H, et al. (2002) Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105:509-515.
13. Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690-694.
14. Kalsotra A, Anakk S, Boehme CL, and Strobel HW (2002) Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. Drug Metab Dispos 30:1022-1028.
15. Karara A, Dishman E, Falck JR, and Capdevila JH (1991) Endogenous epoxyeicosatrienoyl-phospholipids: a novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J Biol Chem 266:7561-7569.
16. Kralova E, Mokran T, Murin J, and Stankovicova T (2008) Electrocardiography in two models of isoproterenol-induced left ventricular remodelling. Physiol Res 57 (Suppl 2):583-589.
17. Kroetz DL and Xu F (2005) Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol 45:413-438.
18. Laethem RM, Balazy M, Falck JR, Laethem CL, and Koop DR (1993) Formation of 19(S)-,19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J Biol Chem 268:12912-12918.
19. Lee SJ, Landon CS, Nazian SJ, and Dietz JR (2004) Cytochrome P-450 metabolites in endothelin-stimulated cardiac hormone secretion. Am J Physiol Regul Integr Comp Physiol 286:R888-R893.
20. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
21. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
22. Magga J, Vuolteenaho O, Tokola H, Marttila M, and Ruskoaho H (1998) B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann Med 30 (Suppl 1):39-45.
23. Masson S, Arosio B, Luvarà G, Gagliano N, Fiordaliso F, Santambrogio D, Vergani C, Latini R, and Annoni G (1998) Remodelling of cardiac extracellular matrix during beta-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. J Mol Cell Cardiol 30:1505-1514.
24. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gösele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, et al. (2008) Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40:529-537.
25. Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, and Kroetz DL (2007) Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos 35:1126-1134.
26. Nithipatikom K, Grall AJ, Holmes BB, Harder DR, Falck JR, and Campbell WB (2001) Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem 298:327-336.
27. Ritter O and Neyses L (2003) The molecular basis of myocardial hypertrophy and heart failure. Trends Mol Med 9:313-321.
28. Rollín R, Mediero A, Fernández-Cruz A, and Fernández-Durango R (2005) Downregulation of the atrial natriuretic peptide/natriuretic peptide receptor-C system in the early stages of diabetic retinopathy in the rat. Mol Vis 11:216-224.
29. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
30. Thum T and Borlak J (2000a) Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. Br J Pharmacol 130:1745-1752.
31. Thum T and Borlak J (2000b) Gene expression in distinct regions of the heart. Lancet 355:979-983.
32. Thum T and Borlak J (2002) Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 16:1537-1549.
33. Wang MH, Guan H, Nguyen X, Zand BA, Nasjletti A, and Laniado-Schwartzman M (1999) Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. Am J Physiol 276:F246-F253.
34. Wang MH, Stec DE, Balazy M, Mastyugin V, Yang CS, Roman RJ, and Schwartzman ML (1996) Cloning, sequencing, and cDNA-directed expression of the rat renal CYP4A2: arachidonic acid omega-hydroxylation and 11,12-epoxidation by CYP4A2 protein. Arch Biochem Biophys 336:240-250.
35. Wang S, Hartley DP, Ciccotto SL, Vincent SH, Franklin RB, and Kim MS (2003) Induction of hepatic phase II drug-metabolizing enzymes by 1,7-phenanthroline in rats is accompanied by induction of MRP3. Drug Metab Dispos 31:773-775.
36. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, et al. (2006) Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 103:18733-18738.
37. Zordoky BN and El-Kadi AO (2007) H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods 56:317-322.
38. Zordoky BN and El-Kadi AO (2008) Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab 9:122-128.